New eczema drug candidate tested in healthy chinese volunteers

NCT ID NCT06214481

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a single dose of the experimental drug rocatinlimab in 20 healthy Chinese adults. The main goal was to see how the drug moves through the body and whether it is safe. This is a first step toward possibly using the drug to treat atopic dermatitis (eczema) in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rocatinlimab (AMG 451)

What this could lead to

If successful, this study could provide dosing and safety data needed to test rocatinlimab as a potential treatment for atopic dermatitis in Chinese patients.

What could go wrong

This is an early, small study in only 20 healthy people, not patients. It is designed to measure drug levels and safety, not to test if it works for the disease. Side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Huashan Hospital Affiliated to Fudan University?

    Shanghai, 200040, China